Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Jan 2015

Blachly James S, Lozanski Gerard, Lucas David M, Grever Michael R, Kendra Kari, Andritsos Leslie A

Abstract excerpt

The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung adenocarcinomas, papillary thyroid cancer, malignant melanoma, and hairy cell leukemia (HCL). Malignant melanoma and HCL are of particular interest because of both the high proportion of cases harboring the mutation and the dramatic responses to BRAF inhibitor therapy reported in the literature. This report presents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Leukemia, Hairy Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasms, Second Primary

Share to Oximes

Share to Positron-Emission Tomography

Share to Proto-Oncogene Proteins B-raf

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 25583765
DOI: 10.6004/jnccn.2015.0004
PMCID: PMC7250239

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.PMID 25583765Read ↗

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.Semantic proximity Read ↗

BRAF mutation in hairy cell leukemiaSemantic proximity Read ↗

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activitySemantic proximity Read ↗

[Molecular and therapeutic advances in Hairy cell leukemia].Semantic proximity Read ↗

Non-V600E BRAF mutations and treatment for hairy cell leukemia.Semantic proximity Read ↗

Non-canonical BRAF variants and rearrangements in hairy cell leukemia.Semantic proximity Read ↗

BRAF inhibitor therapy in HCL.Semantic proximity Read ↗

BRAF V600E mutation in hairy cell leukemia: from bench to bedsideSemantic proximity Read ↗

Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.Semantic proximity Read ↗

Targetable Mutations in BRAF V600E–Negative Hairy-Cell LeukemiaSemantic proximity Read ↗

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.Semantic proximity Read ↗

Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.